GLP-1, incretin multi-agonist and amylin trial starts

RecordSTO-B1QTK9GEHF-12DA1ZGFBQ-RRPP7S

United States · 2021

GLP-1, incretin multi-agonist and amylin trial starts in the United States was 51 in 2021 (ClinicalTrials.gov).

Publisher: ClinicalTrials.gov
Authority tier: T1 Official
Report: ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in the United States
Locator: totalCount field of the API response. Query: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in the United States.
Retrieved: 27 Sep 2026
Status: Verified

What the source says

{"totalCount":51,"studies":[
ClinicalTrials.gov (U.S. National Library of Medicine), ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in the United States, totalCount field of the API response. Query: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in the United States.

Checked: the figure 51 is stated in this passage. If it does not match, the extraction is wrong and we want to know.

Cite this figure

APA

ClinicalTrials.gov (U.S. National Library of Medicine). (2021). ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in the United States. Retrieved September 27, 2026, from https://clinicaltrials.gov/api/v2/studies?query.intr=semaglutide%20OR%20tirzepatide%20OR%20retatrutide%20OR%20orforglipron%20OR%20survodutide%20OR%20cagrilintide%20OR%20CagriSema%20OR%20mazdutide%20OR%20liraglutide%20OR%20dulaglutide%20OR%20exenatide%20OR%20ecnoglutide%20OR%20danuglipron%20OR%20pemvidutide%20OR%20amycretin%20OR%20efinopegdutide%20OR%20MariTide%20OR%20maridebart%20OR%20petrelintide%20OR%20%22GLP-1%20receptor%20agonist%22%20OR%20LY3437943%20OR%20LY3502970%20OR%20%22BI%20456906%22%20OR%20LY3298176%20OR%20IBI362%20OR%20%22AMG%20133%22%20OR%20%22NNC0487-0111%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2021-01-01%2C2021-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId. Via StatOrigin, https://statorigin.org/stat/stat_B1QTK9GEHF12DA1ZGFBQRRPP7S

Other formats: MLA, Chicago, BibTeX

MLA: ClinicalTrials.gov (U.S. National Library of Medicine). "ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in the United States." 2021, https://clinicaltrials.gov/api/v2/studies?query.intr=semaglutide%20OR%20tirzepatide%20OR%20retatrutide%20OR%20orforglipron%20OR%20survodutide%20OR%20cagrilintide%20OR%20CagriSema%20OR%20mazdutide%20OR%20liraglutide%20OR%20dulaglutide%20OR%20exenatide%20OR%20ecnoglutide%20OR%20danuglipron%20OR%20pemvidutide%20OR%20amycretin%20OR%20efinopegdutide%20OR%20MariTide%20OR%20maridebart%20OR%20petrelintide%20OR%20%22GLP-1%20receptor%20agonist%22%20OR%20LY3437943%20OR%20LY3502970%20OR%20%22BI%20456906%22%20OR%20LY3298176%20OR%20IBI362%20OR%20%22AMG%20133%22%20OR%20%22NNC0487-0111%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2021-01-01%2C2021-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId. Accessed 27 Sept. 2026 via StatOrigin, https://statorigin.org/stat/stat_B1QTK9GEHF12DA1ZGFBQRRPP7S.
Chicago: ClinicalTrials.gov (U.S. National Library of Medicine). "ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in the United States." 2021. https://clinicaltrials.gov/api/v2/studies?query.intr=semaglutide%20OR%20tirzepatide%20OR%20retatrutide%20OR%20orforglipron%20OR%20survodutide%20OR%20cagrilintide%20OR%20CagriSema%20OR%20mazdutide%20OR%20liraglutide%20OR%20dulaglutide%20OR%20exenatide%20OR%20ecnoglutide%20OR%20danuglipron%20OR%20pemvidutide%20OR%20amycretin%20OR%20efinopegdutide%20OR%20MariTide%20OR%20maridebart%20OR%20petrelintide%20OR%20%22GLP-1%20receptor%20agonist%22%20OR%20LY3437943%20OR%20LY3502970%20OR%20%22BI%20456906%22%20OR%20LY3298176%20OR%20IBI362%20OR%20%22AMG%20133%22%20OR%20%22NNC0487-0111%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2021-01-01%2C2021-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId. Accessed September 27, 2026. Cited from StatOrigin, https://statorigin.org/stat/stat_B1QTK9GEHF12DA1ZGFBQRRPP7S.
BibTeX: @misc{clinicaltrialsgo2021ctgovrrpp7s, author = {{ClinicalTrials.gov (U.S. National Library of Medicine)}}, title = {ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in the United States}, year = {2021}, howpublished = {StatOrigin, https://statorigin.org}, url = {https://statorigin.org/stat/stat_B1QTK9GEHF12DA1ZGFBQRRPP7S}, note = {Original source: https://clinicaltrials.gov/api/v2/studies?query.intr=semaglutide\%20OR\%20tirzepatide\%20OR\%20retatrutide\%20OR\%20orforglipron\%20OR\%20survodutide\%20OR\%20cagrilintide\%20OR\%20CagriSema\%20OR\%20mazdutide\%20OR\%20liraglutide\%20OR\%20dulaglutide\%20OR\%20exenatide\%20OR\%20ecnoglutide\%20OR\%20danuglipron\%20OR\%20pemvidutide\%20OR\%20amycretin\%20OR\%20efinopegdutide\%20OR\%20MariTide\%20OR\%20maridebart\%20OR\%20petrelintide\%20OR\%20\%22GLP-1\%20receptor\%20agonist\%22\%20OR\%20LY3437943\%20OR\%20LY3502970\%20OR\%20\%22BI\%20456906\%22\%20OR\%20LY3298176\%20OR\%20IBI362\%20OR\%20\%22AMG\%20133\%22\%20OR\%20\%22NNC0487-0111\%22\&filter.advanced=AREA\%5BStudyType\%5DINTERVENTIONAL\%20AND\%20AREA\%5BStartDate\%5DRANGE\%5B2021-01-01\%2C2021-12-31\%5D\%20AND\%20AREA\%5BLocationCountry\%5D\%22United\%20States\%22\&countTotal=true\&pageSize=1\&fields=NCTId. Accessed September 27, 2026.} }

Data published under CC BY 4.0. The citation credits the original publisher and links to this permanent record.

Provenance and verification

Everything needed to check this number yourself, without taking our word for it.

Primary source

Publisher: ClinicalTrials.gov (U.S. National Library of Medicine) · homepage ↗
Authority tier: Tier 1 · Multilateral Official
Report: ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in the United States
Type: Dataset
Published: —
Locator: totalCount field of the API response. Query: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in the United States.
Retrieved: 27 September 2026
Link status: Reachable (HTTP 200)
Report licence: Public domain

Verification

Status: Verified
Review protocol: pipeline:ctgov-api-totalcount-verified
Checked on: 27 September 2026
Last revision: 27 September 2026
Permanent URL: /stat/stat_B1QTK9GEHF12DA1ZGFBQRRPP7S

This figure in context

Cited in

GLP-1 and the obesity drug pipeline: where the next generation is being tested

Go further

Record last modified 27 September 2026. Value type: actual. Update cadence: irregular. This page is permanently addressable at statorigin.org/stat/stat_B1QTK9GEHF12DA1ZGFBQRRPP7S.

Country or region	Value	Source	Details
Global	101	ClinicalTrials.gov	Open record
China	18	ClinicalTrials.gov	Open record